Thrombopoietin Receptor Agonist (TPO-RA)
Avatrombopag
Brand names: Doptelet
Adult dose
Dose: Thrombocytopenia in chronic liver disease before procedures: 40 mg or 60 mg once daily for 5 days (dose based on platelet count; 40 mg if platelets 40–<50 × 10⁹/L; 60 mg if <40 × 10⁹/L). Start 10–13 days before procedure. Chronic immune thrombocytopenia (ITP): 20 mg once daily, titrated
Route: Oral
Frequency: Once daily (with food)
Clinical pearls
- Indicated for: (1) thrombocytopenia in chronic liver disease before elective procedures (to reduce transfusion need); (2) chronic immune thrombocytopenia (ITP) after other treatments
- NICE TA639 (2020): avatrombopag for ITP in adults
- NICE TA609 (2020): avatrombopag for thrombocytopenia in chronic liver disease
- Platelet response typically peaks 10–13 days after the 5-day course — time procedure accordingly
- VTE risk in hepatic disease is significant — risk:benefit assessment mandatory; short course only
- Does not require food for ITP use; food increases bioavailability for liver disease indication
Contraindications
- Hypersensitivity to avatrombopag
- Portal vein thrombosis risk in hepatic disease (use with caution — TPO-RA increases thromboembolic risk)
Side effects
- Thromboembolic events (DVT, PE, portal vein thrombosis — especially in liver disease)
- Headache
- Fatigue
- Nausea
- Pyrexia
Interactions
- Dual CYP2C9 and CYP3A4 inhibitors/inducers — affect avatrombopag levels (see SmPC)
- CYP3A4 inducers (rifampicin) — reduce avatrombopag levels
Monitoring
- Platelet count (before, during, and after treatment)
- Signs of thromboembolism (especially in chronic liver disease)
- FBC
- LFTs
Reference: BNF; NICE TA639 (Avatrombopag for ITP, 2020); NICE TA609 (Avatrombopag for chronic liver disease thrombocytopenia, 2020); BSH ITP Guidelines (2019 updated); https://bnf.nice.org.uk/drugs/avatrombopag/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO